Why Outset Medical, Inc.’s (OM) Stock Is Up 5.32%
As of Tuesday, July 28, Outset Medical, Inc.’s OM share price has surged by 5.32%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Commentary & Analysis
Why Outset Medical, Inc.’s (OM) Stock Is Up 5.07%
As of Monday, July 27, Outset Medical, Inc.’s OM share price has surged by 5.07%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Outset Medical, Inc.’s (OM) Stock Is Down 7.41%
As of Wednesday, July 08, Outset Medical, Inc.’s OM share price has dipped by 7.41%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Outset Medical, Inc.’s (OM) Stock Is Up 5.51%
As of Monday, July 06, Outset Medical, Inc.’s OM share price has surged by 5.51%, which has investors questioning if this is right time to sell.Michael Rose
Why Outset Medical, Inc.’s (OM) Stock Is Up 6.63%
As of Thursday, July 02, Outset Medical, Inc.’s OM share price has surged by 6.63%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | OM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $88.1 | $334.8 | 21% |
|
| Shares Out (Mil) | 18.4 | 41.7 | 29% |
|
| Institutional Ownership | 96.3% | 77.3% | 70% |
|
| Float (Mil) | 15.5 | 34.7 | 25% |
|
| Beta | 1.91 | 0.86 | 91% |
|
| Avg Daily Volume (000s) | 107 | 266 | 37% |
|
| Price Change (52-week) |
(72.9%) | 60.7% | 8% |
|
| Growth | OM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.1% | 11.8% | 80% |
|
| Net Income (5yr) | 7.6% | (5.8%) | 51% |
|
| EPS (5yr) | 40.6% | 10.7% | 89 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (16.1%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.717) | ($2.913) | ($2.183) | |
| Month Ago EPS | ($0.717) | ($2.893) | ($2.180) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.747) | ($2.857) | ($2.380) | |
| Year/Year Chg | (30.6%) | (45.7%) | (66.9%) | |
| Financials | OM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $118 | $152 | 28% |
|
| Net Income (TTM) (Mil) | ($75) | ($11) | 13% |
|
| EPS (TTM) | ($4.148) | ($0.500) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($34) | ($2) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($45) | $1 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $100 | $22 | 45% |
|
| Enterprise Value (Q1) (Mil) | $13 | $304 | 9% |
|
| Valuation | OM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.79 | 2.88 | 16% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | OM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 40.6% | 59.1% | 51% |
|
| Net Margin | (63.7%) | (7.7%) | 10% |
|
| ROA | (27.2%) | (13.7%) | 18% |
|
| ROE | (53.9%) | (15.9%) | 15% |
|
| Liabilities to Assets | 55.2% | 44.9% | 48% |
|
| F-Score | 4 | 4 | 34% |
|
Outset Medical, Inc. did not pass any screens on 7/30/2026.
